Committees

Business Development & Finance Committee

Charter

The Business Development & Finance Committee (BDF) strives to:

  • address the evolving CGT business model and key considerations including clinical development, partnerships, financing, and commercialization.

Projects & Objectives

  • The BDF champions the ISCT Investigators to Investors (I to I) program, which strives to bridge the knowledge gap between investigators and investors within the cell and gene therapy (CGT) sector. 
  • Conducts semi-annual surveys with aim to understand investor perceptions of key opportunities and challenges in the CGT field at the time.
  • Curates topical educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing for both the investor and investigator profiles 

Ideal Member Profile

  • Business development executives (e.g., CEOs, SVPs/VPs, etc.)
  • Cell and Gene Therapy investors & analysts, by invitation

Recent Publications

Cell and gene therapy: a snapshot of investor perspectives (Cytotherapy. 2021 May; 23(3):256-260)
A roadmap for cost-of-goods planning to guide economic production of cell therapy products (Cytotherapy. 2017 Dec;19(12):1383-1391)

The Committee

Headshot of Sven Kili

Co-Chair

Sven Kili, MBChB, MRCS (Eng)

Sven Kili Consulting
Saisei Ventures
CCRM 
United Kingdom

Headshot of Patrick Rivers

Co-Chair

Patrick Rivers, MBA

Aquilo Capital
United States

2022 Members

Sasha Aleksic
FUJIFILM
United States

Gad Berdugo
Explorium Capital
United States

Kensuke Amemiya
Hitachi
Japan

Attilio Bondanaza
AstraZeneca
Sweden

Greg Crescenzi
Kytopen
United States

Sybil Danby
Centre for Breakthrough Medicines
USA

Frederic Faiz
G Con
Europe

Suzanne Farid, PhD

University College London
England

Miguel Forte
Bone Therapeutics
Belgium

Asthika Goonewardene
Truist Securities
United States

Isaac Haq
Archimed
USA

Brian Hawkins, PhD
Pluristyx
United States

Thomas Heathman

Ori Biotech
United Kindgom

Jack Horgan
MaxCyte
USA

Michelle Janszak
Sartorius
USA

Troels Jordansen
Glycostem
Netherlands

Maximiliano Kunze Küllmer, MEng
Cells for Cells
Chile
ESP Leadership Development Programme

Amy Lamperti
BioCentriq
USA


Robert Margolin
Akron
USA

David Lewandowksi
Azenta
USA

Sophie Bardy
BioBridge
USA

Anne Brady
Avectas
USA

Susan Nichols
ViroCell
UK

Julia Zhen
ThermoFisher
USA

Michael May, PhD
CCRM
Canada

Bill Milligan 
AventaCell
Canada/ Taiwan

Lise Munsie 
CCRM
United States

Joseph Oved 
MSK
United States

Jean-Sebastian Parisse
Aseptic Technologies
Belgium

Caytlin Perlin

cGMPnow
United States

Bryan Potilove
Broadoak
United States

Caroline Rand
cGMPnow
United States

Karolis Rosickas
Regeneus
Australia

Kyle Ritchie
OmniaBio
Canada

Christian Rouldan
Cellares
United States

Mark Sawicki

Cryoport
United States

Antonio Scatena
Gateway Analytical
United States

Mathias Svahn
NextCell Pharma
Germany

David Smith, PhD

Akron Biotech
United States

Dan Smith
Charles River
United States

Nathan Smith
Cell Therapies PTY
Australia

Jennifer Solomon
STEMCELL
Canada

Ashley Stanoszek
Gateway Analytical
United States

Steven Thompson
BioLife
United States

Harmut Tintrup
Lonza
United States

Phil Vanek, PhD
Gamma Biosciences
United States 

Tim Vickers
GConBio
United States

Jonathan Yeh
SaiSei Ventures
Canada

Fadi Eskandar
Santen
USA